Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, Mass 02115, USA.
J Vasc Surg. 2010 Apr;51(4):962-71. doi: 10.1016/j.jvs.2009.11.037.
Varicose veins (VarVs) are a common disorder of venous dilation and tortuosity with unclear mechanism. The functional integrity and the ability of various regions of the VarVs to constrict is unclear. This study tested the hypothesis that the different degrees of venodilation in different VarV regions reflect segmental differences in the responsiveness to receptor-dependent vasoconstrictive stimuli and/or in the postreceptor signaling mechanisms of vasoconstriction.
Varix segments and adjacent proximal and distal segments were obtained from patients undergoing VarV stripping. Control great saphenous vein specimens were obtained from patients undergoing lower extremity arterial bypass and coronary artery bypass grafting. Circular vein segments were equilibrated under 2 g of tension in a tissue bath, and changes in isometric constriction in response to angiotensin II (AngII, 10(-11)-10(-7) M), phenylephrine (PHE, 10(-9)-10(-4) M), and KCl (96 mM) were recorded. The amount of angiotensin type 1 receptor (AT(1)R) was measured in vein tissue homogenate.
AngII caused concentration-dependent constriction in control vein (max 35.3 +/- 9.6 mg/mg tissue, pED(50) 8.48 +/- 0.34). AngII caused less contraction and was less potent in proximal (max 7.9 +/- 2.5, pED(50) 6.85 +/- 0.61), distal (max 5.7 +/- 1.2, pED(50) 6.74 +/- 0.68), and varix segments of VarV (max 7.2 +/- 2.0, pED(50) 7.11 +/- 0.50), suggesting reduced AT(1)R-mediated contractile mechanisms. VarVs and control veins had similar amounts of AT(1)R. alpha-adrenergic receptor stimulation with PHE caused concentration-dependent constriction in control veins (max 73.0 +/- 13.9 mg/mg tissue, pED(50) 5.48 +/- 0.12) exceeding that of AngII. PHE produced similar constriction and was equally potent in varix and distal segments but produced less constriction and was less potent in proximal segments of VarVs (max 32.1 +/- 6.4 mg/mg tissue, pED(50) 4.89 +/- 0.13) vs control veins. Membrane depolarization by 96 mM KCl, a receptor-independent Ca(2+)-dependent response, produced significant constriction in control veins and similar contractile response in proximal, distal, and varix VarV segments, indicating tissue viability and intact Ca(2+)-dependent contraction mechanisms.
Compared with control veins, different regions of VarV display reduced AngII-mediated venoconstriction, which may be involved in the progressive dilation in VarVs. Postreceptor Ca(2+)-dependent contraction mechanisms remain functional in VarVs. The maintained alpha-adrenergic responses in distal and varix segments, and the reduced constriction in the upstream proximal segments, may represent a compensatory adaptation of human venous smooth muscle to facilitate venous return from the dilated varix segments of VarV.
静脉曲张(VarVs)是一种静脉扩张和扭曲的常见疾病,其机制尚不清楚。VarVs 不同区域的功能完整性和收缩能力尚不清楚。本研究检验了以下假设:不同 VarV 区域的不同程度的静脉扩张反映了对受体依赖性血管收缩刺激的反应以及血管收缩的受体后信号机制在各区域存在分段差异。
从接受静脉曲张剥脱术的患者中获取静脉曲张段及相邻的近端和远端段。从接受下肢动脉旁路和冠状动脉旁路移植术的患者中获取对照大隐静脉标本。将环状静脉段在组织浴中以 2 克的张力平衡,并记录对血管紧张素 II(AngII,10(-11)-10(-7) M)、苯肾上腺素(PHE,10(-9)-10(-4) M)和 KCl(96 mM)的等长收缩反应的变化。测量静脉组织匀浆中的血管紧张素 1 型受体(AT(1)R)的量。
AngII 在对照静脉中引起浓度依赖性收缩(最大 35.3 +/- 9.6 mg/mg 组织,pED(50) 8.48 +/- 0.34)。AngII 在近端(最大 7.9 +/- 2.5,pED(50) 6.85 +/- 0.61)、远端(最大 5.7 +/- 1.2,pED(50) 6.74 +/- 0.68)和静脉曲张的静脉段中引起的收缩较少,作用较弱(最大 7.2 +/- 2.0,pED(50) 7.11 +/- 0.50),表明 AT(1)R 介导的收缩机制减少。VarVs 和对照静脉具有相似数量的 AT(1)R。PHE 刺激α-肾上腺素能受体引起对照静脉的浓度依赖性收缩(最大 73.0 +/- 13.9 mg/mg 组织,pED(50) 5.48 +/- 0.12),超过 AngII。PHE 在静脉曲张和远端段中产生相似的收缩作用,且作用强度相同,但在近端段中产生的收缩作用较弱,作用强度也较低(最大 32.1 +/- 6.4 mg/mg 组织,pED(50) 4.89 +/- 0.13)与对照静脉相比。96 mM KCl 引起的膜去极化,一种受体非依赖性 Ca(2+)-依赖性反应,在对照静脉中产生显著收缩,并在近端、远端和静脉曲张的静脉段中产生相似的收缩反应,表明组织活力和完整的 Ca(2+)-依赖性收缩机制。
与对照静脉相比,VarV 的不同区域显示出 AngII 介导的静脉收缩减少,这可能与 VarV 中的渐进性扩张有关。VarV 中的受体后 Ca(2+)-依赖性收缩机制仍然保持功能。在远端和静脉曲张段中保留的α-肾上腺素能反应,以及在上游近端段中减少的收缩,可能代表人体静脉平滑肌对扩张的静脉曲张段的静脉回流的代偿适应。